Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(13%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_3
2
25%
Ph phase_4
2
25%
Ph phase_2
4
50%

Phase Distribution

0

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)
Phase 4Post-market surveillance
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(4)
Other(1)

Detailed Status

Completed4
Enrolling by invitation1
Recruiting1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (50.0%)
Phase 32 (25.0%)
Phase 42 (25.0%)

Trials by Status

completed450%
enrolling_by_invitation113%
recruiting113%
not_yet_recruiting113%
unknown113%

Recent Activity

1 active trials
Showing 5 of 8
enrolling_by_invitationphase_3

A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder

NCT06878976
recruitingphase_2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970
completedphase_2

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

NCT06404099
completedphase_4

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

NCT04789174
completedphase_2

RECOVER-SLEEP: Platform Protocol

NCT06404086
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06878976Phase 3

A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder

Enrolling By Invitation
NCT06170970Phase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

Recruiting
NCT06404099Phase 2

RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)

Completed
NCT04789174Phase 4

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study

Completed
NCT06404086Phase 2

RECOVER-SLEEP: Platform Protocol

Completed
NCT06103825Phase 3

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

Completed
NCT06590662Phase 2

Efficacy and Tolerance of Solriamfetol in Patients Affected with Idiopathic Hypersomnia.

Not Yet Recruiting
NCT04602936Phase 4

Solriamfetol in Binge Eating Disorder

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8